Quidel has developed an innovative line of respiratory products for decades.
So whatever respiratory season may bring, we’re ready.
1979 founded Quidel
Receives FDA
1999 y Õiâ> /iÃÌ ƂÉ ® y Õ ÌiÃÌ +ÕV6Õi
clearance for world’s w ÀÃÌ À>«` `>}ÃÌV
2015 Solana assays Introduction of
,iViÛià -Ƃ,- ƂÌ}i 2020 -Ƃ,- 6Ó
Ƃ 1Ƃ vÀ -w > Ó Ƃ] -w > Ó Õ³
SARS FIA (ABC), QuickVue SARS Antigen Test, and Solana
2011 automated analyzer FIA +Õ`i >ÕVià -w >
First company to receive
1996 +ÕV6Õi i -ÌÀi« Ƃ /iÃÌ CLIA waiver for Strep A with
2018 which meets FDA’s Class II +ÕV6Õi y Õiâ> Ƃ³
RIDT requirements Receives FDA clearance for
QuickVue® y Õiâ> Ƃ³ ] ,-6] SARS* Antigen Assays
Solana® y Õiâ> Ƃ³ ] ,-6 ³ *6] -Ƃ,- 6ÓI]
À`iÌi> Complete Assays To get the right RIDT for your patient, contact a Quidel Inside Sales at 858.431.5814 or visit
quidel.com
*THESE TESTS ARE AVAILABLE FOR SALE IN THE USA UNDER EMERGENCY USE AUTHORIZATION. These SARS tests have not been FDA cleared or approved, but have been authorized LÞ Ìi Ƃ Õ`iÀ > iÀ}iVÞ 1Ãi ƂÕÌÀâ>Ì 1Ƃ® vÀ ÕÃi LÞ >ÕÌÀâi` >LÀ>ÌÀià vÀ Ìi `iÌiVÌ v «ÀÌià +ÕV6Õi >` -w >® À ÕViV >V`à ->>® vÀ -Ƃ,- 6Ó] Ì for any other viruses or pathogens. These tests are only authorized for the duration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection >`ÉÀ `>}Ãà v "6 £ Õ`iÀ -iVÌ xÈ{L®£® v Ìi i`iÀ> `] ÀÕ} >` ÃiÌV ƂVÌ] Ó£ 1°-° ° Å ÎÈäLLLÎL®£®] ÕiÃà ÌiÀ>Ìi` À ÀiÛi` ÃiÀ°
Ƃ £ä£nÎÈää ää äÈÉÓÓ®
5QƂ C®
5QƂ C
y Õiâ> Ƃ³ ] ,-6] -Ƃ,-I Antigen, Õ ³ -Ƃ,-I ƂÌ}i ƂÃÃ>ÞÃ
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52